Target
NSCLC
4 abstracts
Abstract
Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC).Org: Foresight Diagnostics,
Abstract
Comparative survival after neoadjuvant vs adjuvant systemic therapy in resectable stage II and stage III non-small cell lung cancer: A retrospective study using the National Cancer Database.Org: Department of Public Health & Preventive Medicine,
Abstract
Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Ohio State University Wexner Medical Center, University of Rochester Medical Center,
Abstract
Reporting of patient reported outcomes in randomized clinical trials (RCTs) in non-small cell lung cancer (NSCLC) patients (pts).Org: Syneos Health, Syneos Health France, Syneos Health Portugal, Syneos Health Israel,